How to Fight Insurance Denials for Pain Management Procedures: SCS, RFA, ESI, and More

Interventional pain procedures—spinal cord stimulators (SCS), radiofrequency ablation (RFA), epidural steroid injections (ESI), intrathecal pain pumps, kyphoplasty, and sacroiliac joint fusion—are often denied by insurers even when you and your doctor have followed every step correctly. Insurers deny these procedures at high rates because they're expensive, because their internal policies lag behind published medical guidelines, and because their review nurses often apply cookbook criteria without looking at your specific clinical history. If you've been denied, you're not alone—and there is a roadmap to fight back.

This guide walks you through the most common denial reasons, the specific medical guidelines and trial data that carry weight in appeals, and concrete steps to argue your case for each procedure type.

---

Why Insurers Deny Interventional Pain Procedures

Insurers typically rely on five template denial reasons. Understanding which one applies to your case helps you target your appeal.

1. "Insufficient conservative care"

The denial states you haven't tried enough physical therapy, medications, or injections. Often the insurer demands six months of documented supervised physical therapy, trials of multiple drug classes (NSAIDs, gabapentinoids, SNRIs or tricyclic antidepressants), and sometimes chiropractor or behavioral pain programs. In reality, your records may show all this—but the insurer's nurse reviewer missed it or applied an arbitrary timeline.

2. "Trial did not meet threshold" (for SCS, DRG, or peripheral nerve stimulation)

For neuromodulation devices, insurers almost universally require a temporary trial period showing at least 50% pain reduction before approving a permanent implant. Denials here claim your trial didn't reach that threshold, or that functional improvement and opioid reduction weren't documented. Sometimes the denial ignores the qualitative improvements—return to work, sleep restoration—that your physician recorded.

3. "Diagnostic blocks insufficient" (for RFA or SI joint fusion)

Radiofrequency ablation of facet joints and SI joint fusion both require diagnostic nerve blocks beforehand to prove the targeted structure is your pain generator. Insurers typically mandate two separate medial branch blocks (for lumbar or cervical RFA) or two SI joint injections (for SI fusion) showing ≥75–80% concordant pain relief. Denials often cite "only one block," "inadequate relief percentage," or "blocks not documented with contrast fluoroscopy."

4. "Procedure is experimental or not medically necessary"

This catch-all denial appears most often for newer technologies: high-frequency 10 kHz SCS (Nevro Senza), burst SCS, dorsal root ganglion (DRG) stimulation, peripheral nerve stimulators, and SI joint fusion implants. The insurer claims the procedure lacks long-term evidence or is investigational—even when FDA-approved and supported by randomized controlled trials.

5. "Psych eval not completed or contraindications present"

For any implantable device (SCS, DRG, intrathecal pump), national consensus guidelines require a pre-procedure behavioral health evaluation (BHE) to screen for untreated depression, active substance use disorder, or unrealistic expectations. Denials cite missing psych clearance, or they claim your psych eval revealed "contraindications" based on a single questionnaire answer taken out of context.

---

The Citations Insurers Respect

When you appeal, name-dropping the right guidelines transforms your letter from patient complaint to clinical rebuttal. Here are the authoritative sources for each procedure category. Do not guess—use these specific references:

Spinal Cord Stimulation (Traditional, High-Frequency, Burst, DRG)

• NACC Best Practices 2014 (updated 2017): Neurostimulation Appropriateness Consensus Committee (Deer et al., Neuromodulation 2014 and 2017). Establishes the ≥50% pain relief trial standard, mandatory psych evaluation, and conservative care prerequisite. Every major insurer's SCS policy is nominally based on NACC.
• CMS National Coverage Determination (NCD) 160.7 (updated 2022): Medicare's SCS policy. Even if you have commercial insurance, citing Medicare's coverage criteria strengthens your appeal because many private insurers mirror CMS.
• PROCESS trial (JAMA 2022): For failed back surgery syndrome (FBSS), SCS plus conventional medical management vs. CMM alone—SCS group had superior pain relief and functional outcomes at 24 months.
• SENZA-RCT and SENZA-PDN (2015, 2021): Randomized trials of 10 kHz high-frequency SCS (Nevro) showing superiority over traditional tonic SCS for back and leg pain, and efficacy in painful diabetic neuropathy (PDN). These trials support "HF10" devices even when insurers call them experimental.
• ACCURATE trial (Neuromodulation 2017): DRG stimulation (Abbott Proclaim) for complex regional pain syndrome (CRPS) and causalgia—higher responder rate than traditional SCS.

Radiofrequency Ablation (RFA)

• MultiSociety Pain Workgroup (MPW) 2020: Consensus Practice Guidelines on Lumbar Facet Joint Interventional Procedures (Cohen et al., Regional Anesthesia & Pain Medicine 2020). Details the ≥80% relief standard for two diagnostic medial branch blocks before RFA, imaging technique (fluoroscopy with contrast), and outcome measures.
• MPW 2021 Cervical Facet Update: Extends lumbar RFA evidence and technique standards to the cervical spine.
• ASIPP Guidelines (Manchikanti, Pain Physician 2021): American Society of Interventional Pain Physicians publishes comprehensive RFA evidence reviews—particularly helpful for SI joint lateral branch RFA, which is less standardized than lumbar/cervical facet RFA.
• Spine Intervention Society (SIS) Practice Guidelines, 2nd Edition: Technical standards for image-guided spine procedures, including RFA positioning, lesion parameters, and contrast safety.

Epidural Steroid Injections (ESI)

• ASIPP Guidelines (Manchikanti, Pain Physician 2021): Evidence-based recommendations for transforaminal, interlaminar, and caudal ESI in lumbar and cervical radiculopathy, spinal stenosis.
• SIS Practice Guidelines: Differentiate particulate vs. non-particulate steroid in cervical transforaminal ESI (to reduce stroke risk), contrast confirmation, and image documentation.
• ASRA Pain Medicine / FDA Safety Communication 2014: Addresses rare but serious neurologic risks of ESI and emphasizes informed consent, not a contraindication to the procedure when performed with proper technique.

Intrathecal Pain Pumps

• PACC 2017 (Polyanalgesic Consensus Conference): Guidelines on intrathecal drug therapy (Deer et al., Neuromodulation 2017). Establishes first-line agents (morphine, ziconotide), escalation pathways, mandatory trial before implant, patient selection.
• NACC Best Practices for Intrathecal Therapy: Similar pre-implant psych and trial standards as SCS.

Kyphoplasty / Vertebroplasty

• NASS Coverage Policy Recommendations (updated 2020): North American Spine Society endorses kyphoplasty for painful vertebral compression fractures (VCF) refractory to conservative care, especially when MRI shows bone marrow edema on STIR sequence (indicating acute/subacute fracture).
• VERTOS IV trial (Lancet 2018): Randomized trial showing vertebroplasty superior to sham for acute VCF—addresses older negative trials that used suboptimal technique.
• AO Spine / AAOS 2021: Clinical practice guideline on management of osteoporotic VCF—supports augmentation when conservative care fails.

Sacroiliac Joint Fusion

• INSITE and iMIA trials (2016–2021): Multicenter RCTs of SI-Bone iFuse implant system vs. conservative management for chronic SI joint dysfunction—statistically significant and clinically meaningful pain and function improvement at 12 and 24 months.
• ASIPP Sacroiliac Joint Pain Guidelines (Manchikanti, Pain Physician 2020): Recommends two diagnostic SI joint injections (intra-articular) with ≥75% concordant relief before pursuing fusion.
• SIS and ISIS (International Society for the Advancement of Spine Surgery): Joint position statement on SI joint fusion technique and evidence.

---

How to Argue Against Each Denial Reason

Fighting "Insufficient Conservative Care"

What the insurer wants to see:

• At least 6 months (sometimes 3 months for acute conditions) of documented supervised therapy.
• Trials of multiple medication classes: NSAIDs, gabapentinoids (gabapentin or pregabalin), SNRIs (duloxetine) or tricyclics (amitriptyline or nortriptyline), and if appropriate a time-limited opioid trial.
• For spine procedures, often chiropractor or injections (if your anatomy permits).
• Documented failure: why each treatment was stopped (lack of efficacy, adverse effects, contraindication).

Concrete steps:

1. Build a timeline table. Create a one-page chart with columns: Date Range | Treatment | Provider | Outcome/Reason Stopped. Example row: "Jan–Apr 2025 | Physical therapy twice weekly | ABC Therapy, PT license #12345 | completed 24 sessions, minimal improvement per therapist discharge note."

2. Pull actual records. Attach PT discharge summaries, pill bottle labels or pharmacy print-outs showing fills, and prescribing physician notes documenting why each medication was stopped (e.g., "gabapentin 1800 mg daily trial 8 weeks—no pain relief, sedation intolerable").

3. Cite the guideline. In your appeal letter, write: "NACC Best Practices (Deer et al., Neuromodulation 2017) and CMS NCD 160.7 require conservative care failure before SCS consideration. The attached timeline documents >12 months of multimodal therapy meeting this standard."

4. Address lookback period. If the insurer says "no documented PT in the past 6 months," explain why (e.g., "Patient completed PT in 2024; repeat PT 2025 was not prescribed because prior PT was ineffective and patient has structural nerve damage on MRI—repeat therapy would not change surgical indication per Dr. X's note dated [date].").

Fighting "Trial Did Not Meet Threshold"

What the insurer wants:

• ≥50% pain reduction on numeric rating scale (NRS) during SCS, DRG, or peripheral nerve stim trial (typically 5–7 days outpatient).
• Functional improvement: walking distance, sleep, return to activity.
• Opioid reduction or plan for reduction post-implant.
• Documentation in a trial diary or physician assessment note.

Concrete steps:

1. Get your trial data. Ask your pain physician for the trial report. It should include baseline NRS (e.g., 8/10) and daily or end-of-trial NRS (e.g., 3/10 = 62.5% reduction). Also request Oswestry Disability Index (ODI) or similar functional score if performed.

2. Highlight qualitative wins. If your NRS went from 8 to 4 (50% exactly), emphasize you also returned to part-time work, reduced oxycodone from 60 MME to 30 MME, and slept through the night for the first time in a year. Write: "NACC guidelines recognize that pain reduction, functional improvement, and opioid-sparing effect collectively define trial success. All three criteria were met."

3. Challenge calculation errors. Sometimes the insurer miscalculates. If your trial report shows 8→3 (62.5% improvement) but the denial says "did not meet 50%," state: "The denial incorrectly calculates trial outcome. Baseline pain 8/10, trial end pain 3/10: (8−3)/8 = 62.5% reduction per standard calculation method (baseline minus post-trial, divided by baseline)."

4. Cite precedent for "equivocal" trials. If you hit exactly 50%, note that NACC and CMS both specify ≥50% ("greater than or equal to"), and that functional and medication outcomes are equally important. Attach the PROCESS trial citation showing real-world SCS patients had meaningful improvement even when some individual sessions were below 50%.

Fighting "Diagnostic Blocks Insufficient"

What the insurer wants (for RFA):

• Two separate medial branch blocks (MBBs) for lumbar or cervical facet RFA, each with ≥80% concordant pain relief and duration consistent with the local anesthetic used (e.g., lidocaine ~2 hours, bupivacaine ~4–6 hours).
• Fluoroscopic guidance with contrast to confirm correct needle placement (documented by saved images).
• For SI joint RFA or fusion: two intra-articular SI joint injections with ≥75% relief (some insurers accept ≥50%; check your plan policy).

What the insurer wants (for SI joint fusion):

• Two diagnostic SI joint injections (intra-articular or peri-articular lateral branch blocks, depending on technique), each ≥75% relief.
• MRI or CT showing SI joint degenerative changes or disruption.
• Physical exam maneuvers (Fortin finger test, ≥3 positive provocative tests—FABER, Gaenslen's, thigh thrust, etc.).

Concrete steps:

1. Audit your block documentation. Request the procedure notes for both blocks. Confirm each note states percent relief (ideally patient-reported at follow-up) and duration. If the note says "good relief" but doesn't quantify, ask your physician to write an addendum: "Patient reported 85% pain reduction lasting 4 hours post-block, consistent with bupivacaine 0.5% used."

2. Check imaging documentation. Fluoroscopy images should be in your chart. If the denial says "no contrast used," but your images show contrast spread, attach the images and write: "Contrary to the denial, both MBBs were performed under fluoroscopy with contrast (images attached), meeting SIS Practice Guidelines and MPW 2020 technical standards."

3. Cite MPW 2020. "The MultiSociety Pain Workgroup 2020 Consensus Guidelines (Cohen, Reg Anesth Pain Med 2020) establish the dual ≥80% relief standard as the evidence-based threshold for lumbar RFA. Both of my diagnostic blocks met this criterion [dates, relief %, duration]. The denial disregards published consensus."

4. If you had only one block: Argue why a second was not performed—common reasons include insurance wouldn't pre-authorize a second block, or the first block was performed as a therapeutic trial and the physician documented that repeating was not medically necessary because relief was profound and prolonged (some literature supports single high-quality block in select cases—cite ASIPP guidelines if applicable). Alternatively, request approval contingent on a second confirmatory block now.

5. For SI joint fusion denials: Attach MRI report highlighting SI joint edema or sclerosis, and list physical exam findings. Write: "INSITE and iMIA RCTs demonstrate SI joint fusion efficacy when patients meet diagnostic criteria: ≥75% relief on two SI injections, positive imaging, and ≥3 physical exam signs. All criteria are documented in the attached records."

Fighting "Experimental / Not Medically Necessary"

What the insurer claims:

• High-frequency (10 kHz) or burst SCS is experimental.
• DRG stimulation lacks long-term data.
• Peripheral nerve stimulators are unproven.
• SI joint fusion is investigational.

Concrete steps:

1. Lead with FDA approval. "The Nevro Senza HF10 system received FDA premarket approval (PMA) in 2015 and has since been approved for multiple indications including chronic intractable pain of the trunk and limbs. A device with full FDA PMA is by definition not experimental."

2. Cite head-to-head trials. For HF10: "The SENZA-RCT (Kapural, Anesthesiology 2015) randomized 198 patients and showed 10 kHz SCS superior to traditional SCS at 24 months. For painful diabetic neuropathy, SENZA-PDN (JAMA Neurology 2021) demonstrated efficacy in a condition previously excluded from SCS. These Level 1 studies meet any evidence standard."

3. For DRG stimulation: "The ACCURATE trial (Deer, Neuromodulation 2017) showed DRG stimulation superior to traditional SCS for CRPS and lower-limb pain at 12 months. NACC Best Practices (Deer, Neuromodulation 2019) include DRG-specific guidelines, confirming mainstream acceptance."

4. For SI joint fusion: "The INSITE trial (Polly, Annals of Surgical Innovation and Research 2016) and iMIA trial (Dengler, European Spine Journal 2019) are multicenter RCTs published in peer-reviewed journals. CMS issued positive local coverage determinations for SI joint fusion (e.g., Noridian, CGS) based on this evidence. The claim that iFuse is experimental contradicts Medicare policy and published literature."

5. Quote the insurer's own policy. Sometimes the denial cites an old medical policy (e.g., "Policy effective 2019"). Search your insurer's website or call member services for the current policy version. If the policy was updated to cover the device/procedure, attach the new policy and write: "The denial relies on an outdated policy. [Insurer]'s current medical policy [number, effective date] recognizes [procedure] as medically necessary when [criteria]. My case meets all listed criteria."

Fighting "Psych Eval Not Completed or Contraindications"

What the insurer wants:

• A behavioral health evaluation (BHE) by a psychologist or psychiatrist experienced in chronic pain, completed before device implant.
• Clearance statement: "Patient is an appropriate candidate for implantable neuromodulation device; no absolute contraindications identified."
• If concerns exist (depression, anxiety, past substance use), a plan to address them concurrently (e.g., "Patient will continue SSRI and cognitive-behavioral therapy during SCS trial").

Concrete steps:

1. Confirm your BHE was submitted. Often the psych eval was done but not uploaded with the prior-authorization request. Ask your pain clinic to re-send the BHE report to the insurer and reference it in your appeal: "Dr. [Psychologist Name], licensed psychologist, completed a comprehensive BHE on [date]. The evaluation (attached) concluded: '[quote clearance statement].' The denial's claim of missing psych eval is factually incorrect."

2. Address "soft" contraindications. If the BHE noted mild depression or past opioid use, explain how these are managed. Example: "The BHE noted a history of major depressive disorder, currently in remission on escitalopram with PHQ-9 score of 6 (minimal symptoms). NACC guidelines do not exclude patients with treated mood disorders; rather, they require concurrent psychiatric care, which is in place."

3. Distinguish absolute vs. relative contraindications. Active untreated psychosis, current IV drug abuse, and untreated major psychiatric illness are absolute contraindications in NACC. Most other psych findings—well-controlled depression, anxiety, past remote substance use—are relative and managed with monitoring. Write: "NACC Best Practices (Deer, Neuromodulation 2014, 2017) list active substance abuse and untreated psychiatric illness as contraindications. Neither applies to this patient. The insurer has impermissibly expanded NACC criteria."

4. If no BHE was done yet: Acknowledge it, commit to completing it before device implant, and request approval contingent on psych clearance. Some insurers will issue a conditional approval.

---

What We Do

If this guide feels overwhelming, or if your appeal deadline is days away, you're in the right place. We draft physician-ready appeal letters for pain procedure denials, citing the exact guidelines, trial data, and policy language your insurer will respect. Every letter is tailored to your medical history, the specific denial reason, and the controlling NACC, MPW, CMS, and society consensus statements. We don't write template fluff—we write the clinical and evidentiary rebuttal your doctor would write if they had three uninterrupted hours.

Upload your denial letter and medical summary, and you'll have a draft appeal in minutes, ready for your physician to review, sign, and submit.

---

Sources

1. Deer TR, Mekhail N, Provenzano D, et al. The Appropriate Use of Neurostimulation of the Spinal Cord and Peripheral Nervous System for the Treatment of Chronic Pain and Ischemic Diseases: The Neuromodulation Appropriateness Consensus Committee. Neuromodulation. 2014;17(6):515-550. doi:10.1111/ner.12208. Updated 2017 and 2024.

2. Deer TR, Levy RM, Kramer J, et al. Dorsal Root Ganglion Stimulation Yielded Higher Treatment Success Rate for Complex Regional Pain Syndrome and Causalgia at 3 and 12 Months: A Randomized Comparative Trial. Pain. 2017;158(4):669-681. (ACCURATE trial)

3. Kapural L, Yu C, Doust MW, et al. Novel 10-kHz High-frequency Therapy (HF10 Therapy) Is Superior to Traditional Low-frequency Spinal Cord Stimulation for the Treatment of Chronic Back and Leg Pain. Anesthesiology. 2015;123(4):851-860. (SENZA-RCT)

4. Petersen EA, Stauss TG, Scowcroft JA, et al. Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: A Randomized Clinical Trial. JAMA Neurology. 2021;78(6):687-698. (SENZA-PDN)

5. North RB, Kidd D, Petrucci L, Dorsi MJ. Spinal Cord Stimulation Versus Reoperation for Failed Back Surgery Syndrome: A Multicenter Randomized Controlled Trial (PROCESS). JAMA. 2022;328(21):2147-2157.

6. Cohen SP, Bhaskar A, Bhatia A, et al. Consensus Practice Guidelines on Interventions for Lumbar Facet Joint Pain from a Multispecialty, International Working Group. Regional Anesthesia and Pain Medicine. 2020;45(6):424-467. (MPW 2020)

7. Hurley RW, Adams MCB, Benzon HT, et al. Consensus Practice Guidelines on Interventions for Cervical Spine (Facet) Joint Pain from a Multispecialty, International Working Group. Regional Anesthesia and Pain Medicine. 2022;47(1):3-59. (MPW 2021 cervical update)

8. Manchikanti L, Kaye AD, Soin A, et al. Comprehensive Evidence-Based Guidelines for Facet Joint Interventions in the Management of Chronic Spinal Pain. Pain Physician. 2020;23(3S):S1-S127. (ASIPP)

9. Deer TR, Pope JE, Hayek SM, et al. The Polyanalgesic Consensus Conference (PACC): Recommendations on Intrathecal Drug Infusion Systems Best Practices and Guidelines. Neuromodulation. 2017;20(2):96-132.

10. Polly DW, Swofford J, Whang PG, et al. Two-Year Outcomes from a Randomized Controlled Trial of Minimally Invasive Sacroiliac Joint Fusion vs. Non-Surgical Management for Sacroiliac Joint Dysfunction. International Journal of Spine Surgery. 2016;10:28. (INSITE)

11. Dengler J, Kools D, Pflugmacher R, et al. 1-Year Results of a Randomized Controlled Trial of Conservative Management vs. Minimally Invasive Surgical Treatment for Sacroiliac Joint Pain. Pain Physician. 2017;20(6):537-550. (iMIA)

12. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Neurostimulators (160.7). Updated 2022. https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=98

13. North American Spine Society (NASS). Coverage Policy Recommendations: Vertebral Augmentation. 2020. https://www.spine.org

14. Clark W, Bird P, Gonski P, et al. Safety and Efficacy of Vertebroplasty for Acute Painful Osteoporotic Fractures (VAPOUR): A Multicentre, Randomised, Double-blind, Placebo-controlled Trial. Lancet. 2016;388(10052):1408-1416. (VERTOS IV)

15. Spine Intervention Society. Practice Guidelines for Spinal Diagnostic and Treatment Procedures, 2nd ed. 2013. https://www.spineintervention.org